Compare Flagstar Bank NA (FLG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs State Street SPDR S&P Biotech ETF — how do they compare? Flagstar Bank NA trades at $14.2 (market cap $5.89B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Flagstar Bank NA pays a 0.28% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Flagstar Bank NA nearer its low. Which is the better fit depends on your goals.
| FLG | XBI | |
|---|---|---|
Market Cap | $5.89B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $15.36 | $164.28 |
52-Week Low | $10.72 | $86.92 |
Dividend Yield | 0.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $14.21, up 1.43% today, with a bullish technical signal from moving averages. The stock shows a low P/B of 0.77 but a high P/E of 473, reflecting recent profitability after a 2025 net loss. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and declared dividends, signaling financial strength. Analyst consensus is a Buy with a $16.85 price target, indicating potential upside from current levels.
The outlook is cautiously optimistic, supported by analyst bullishness and strategic initiatives like technology transformation. Key risks include earnings volatility, competitive pressures in banking, and macroeconomic sensitivity. The stock presents a value opportunity based on price-to-book, but sustained earnings growth is crucial for justifying the elevated P/E ratio.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
